SAN RAFAEL, Calif., June 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
SAN RAFAEL, Calif., June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the New England Journal of Medicine (NEJM) published online today results from a Phase 2 ...
A year of daily subcutaneous vosoritide was associated with a 0.6-inch (1.5-cm) greater increase in height than placebo in children with achondroplasia, the most common form of human dwarfism. There ...
Among 119 children who completed 52 weeks of daily subcutaneous vosoritide, 15 mg/kg, the adjusted mean difference in annualized growth velocity was 1.57 cm/year (95% CI 1.22-1.93, P<0.0001) compared ...
SAN RAFAEL, Calif., April 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to vosoritide injection to improve growth among children aged 5 years or ...
Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. BioMarin Pharmaceutical Inc. is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results